NCT07465757 2026-03-12
ALISCA-Lung2
Puma Biotechnology, Inc.
Phase 2 Not yet recruiting
Clinical Trials
8 trialsNCT06095505 2026-02-17
ALISCA-Lung1
Puma Biotechnology, Inc.
Phase 2 Recruiting
NCT04085315 2024-06-10
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02367352 2019-06-26
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
Phase 1 Terminated
NCT01471964 2018-05-17
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01045421 2016-08-15
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed